Antiphospholipid Syndrome develops as an autoimmune disorder that starts when the body makes antiphospholipid antibodies (aPL). This medical condition connects directly to pregnancy difficulties and blood clotting issues specifically repeated pregnancy loss. APS develops in 5 patients annually for every 100,000 people and appears in 40-50 individuals from every 100,000. A blood test finds aPL antibodies in 13% of stroke survivors and 9.5% of heart attack patients while 6% of people with deep vein blood clots and many pregnant women have APS-related problems.
A key element of APS pathophysiology comes from autoantibodies that target phospholipid-binding proteins particularly β2GPI and prothrombin. Antibodies target endothelial cells to activate blood clotting mechanisms and disrupts natural clot prevention systems. When APS antibodies attack trophoblast cells during pregnancy, they create placental damage and increase pregnancy risks. Inflammatory triggers make the disease process more severe.
Early detection of APS becomes necessary because the condition produces many different symptoms that can harm patients. Our APS diagnostic analysis service at Creative Diagnostics includes advanced testing methods for essential biomarkers.
We use cutting-edge diagnostic techniques, with ELISA as the cornerstone, to ensure high sensitivity and specificity for APS biomarker detection. Our testing methods include:
ELISA (Enzyme-Linked Immunosorbent Assay): The gold standard for antiphospholipid antibody detection, ELISA provides highly sensitive and specific quantification of aCL and aβ2GPI antibodies. It delivers consistent, reproducible results, making it an essential tool for APS risk assessment and disease monitoring. Our advanced ELISA platforms ensure precise differentiation of IgG and IgM subtypes, allowing for early and accurate detection of APS-related biomarkers.
Indirect Immunofluorescence (IIF): Visualizes antibody activity, making it easier to observe and interpret. Used for ANA screening, helping exclude other autoimmune diseases.
Lupus Anticoagulant Testing: Includes dilute Russell viper venom time (dRVVT) and activated partial thromboplastin time (aPTT). Key indicators to assess how aPL affect coagulation, helping determine thrombosis risk.
Western Blot: Primarily used for qualitative detection of β2GPI and associated antigens. Ideal for research applications and confirmation testing, ensuring the accuracy of results.
Protein Chip Technology: A high-throughput platform that can multiplex various aPL tests, including PS/PT and aβ2GPI antibodies. It offers customizable panels for different research needs.
To ensure accurate diagnosis, our testing platform focuses on the following key biomarkers that help confirm APS and predict disease progression:
1. Phosphatidylserine/Prothrombin Complex (PS/PT) Antibody
2. Anti-Cardiolipin Antibody (aCL)
3. Anti-β2-Glycoprotein I Antibody (aβ2GPI)
4. Lupus Anticoagulant (LA)
Gold Standard ELISA Testing: As the globally recognized gold standard for APS antibody detection, ELISA ensures precise quantification of aPL antibodies, offering high specificity and reproducibility. Our ELISA-based assays provide reliable differentiation of IgG and IgM subtypes, aiding in risk assessment and disease monitoring.
Comprehensive aPL Profiling: Simultaneously detect standard aPL (LA, aCL, aβ2GPI) and non-standard aPL (like PS/PT antibodies).
Standardized Reports: Consistent interpretation of results, aligned with international guidelines, ensuring high reliability.
Customizable Panels: Tailored solutions for specific research goals or patient groups. Don't see what you need? Have additional requirements? Contact us to create your customized testing journey.
Our system uses advanced tools and medical knowledge to give you precise results that help you find APS early and create individualized treatment plans. Reach out to us to discover our APS diagnostic services or discuss your needs with our experienced team.
